Market Place
Sourcing Support
Daiichi Prevails On Appeal In ADC Patent Battle With Seagen
04 Dec 2025 //
FIERCE PHARMA
Pfizer Scores Again In Her2-Positive Breast Cancer
14 Oct 2025 //
FIERCE PHARMA
Pfizer`s blockbuster ADC Adcetris nabs FDA nod in LBCL
13 Feb 2025 //
FDA
Ottimo raises $140M to ready PD1/VEGFR2 antibody for clinic
19 Dec 2024 //
FIERCE BIOTECH
Pfizer shares the ADC data that convinced it to start a Phase 3 lung cancer trial
24 May 2024 //
ENDPTS
Pfizer lifts profit view on cost cuts, demand for COVID products
02 May 2024 //
REUTERS
Pfizer`s $43B buyout of ADC specialist Seagen is a done deal
14 Dec 2023 //
FIERCE PHARMA
TUKYSA® Improves Progression-Free Survival in Patients with Breast Cancer
06 Dec 2023 //
BUSINESSWIRE
Overall survival data blur Seagen`s Tukysa-ADC path
06 Dec 2023 //
FIERCE PHARMA
Seagen Highlights First Solid Tumor Data for an ADCETRIS
03 Nov 2023 //
BUSINESSWIRE
Data for ADCETRIS with Combination in Hodgkin Lymphoma to be Featured
02 Nov 2023 //
BUSINESSWIRE
EV-302 Trial Extends OS in Patients Treated with PADCEV & KEYTRUDA in Bladder Cancer
22 Oct 2023 //
BUSINESSWIRE
ESMO: Padcev-Keytruda combo nearly doubles survival in key trial
18 Oct 2023 //
FIERCE PHARMA
Padcev, Keytruda combo posts `practice-changing` win
23 Sep 2023 //
FIERCE PHARMA
Seagen`s breast cancer drug Tukysa boosts Roche`s ADC
17 Aug 2023 //
FIERCE PHARMA
Seagen says Tukysa combo hits main goal in Phase III breast cancer study
17 Aug 2023 //
BUSINESSWIRE
Seagen puts $1.6B Merck-partnered ADC on the back burner
03 Aug 2023 //
FIERCE BIOTECH
Venetoclax Plus Obinutuzumab Demonstrates Durable Survival Benefit
22 Jun 2023 //
PRESS RELAESE
Ph3 Trial of ADCETRIS® (brentuximab vedotin) with Modified Chemo Regimen Shows
20 Jun 2023 //
BUSINESSWIRE
FDA advisers back XBB-targeted COVID shots for 2023-24 campaign
15 Jun 2023 //
REUTERS
6-Year Overall Survival Results Added to Prescribing Information for ADCETRIS
14 Jun 2023 //
BUSINESSWIRE
Seagen touts PhII data for Adcetris combo; A-Alpha partners with Gilead on HIV
13 Jun 2023 //
ENDPTS
Seagen Announces ADCETRIS Plus Novel Immunotherapy Combination Delivers 98% Overall Response Rate
13 Jun 2023 //
BUSINESSWIRE
Seagen CEO Epstein on his next stop, the Pfizer deal and ADCs
08 Jun 2023 //
FIERCE PHARMA
ASCO: Seagen`s top-selling drug under threat from Opdivo
04 Jun 2023 //
FIERCE PHARMA
Biopharma Bets Big on Antibody-Drug Conjugates
08 May 2023 //
BIOSPACE
Seagen Reports First Quarter 2023 Financial Results
27 Apr 2023 //
BUSINESSWIRE
Merck and Seagen`s Padcev-Keytruda combo wins bladder cancer nod
04 Apr 2023 //
PRESS RELEASE
Seagen quietly doles out cell therapy patent rights, but scope remains unclear
16 Mar 2023 //
ENDPTS
Astellas and Seagen Announce China’s NMPA Accepts BLA for Enfortumab Vedotin
09 Mar 2023 //
BUSINESSWIRE
Tiny Corbus pays $7.5M for rival to Seagen`s oncology ADC Padcev
13 Feb 2023 //
FIERCE BIOTECH
Seagen Announces FDA Accelerated Approval of TUKYSA with Trastuzumab
19 Jan 2023 //
BUSINESSWIRE
